Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Cardiovascular Drugs Markets to 2022: Novel Product Launches, Recent Approvals, Research and Development Pipeline, and Blockbuster Drugs -

Research and Markets
Posted on: 21 Mar 18

The "Cardiovascular Drugs: Global Markets to 2022" report has been added to's offering.

The Report Includes an Industry wide Assessment of the Novel Product Launches, Recent Approvals, Research and Development Pipeline, and Blockbuster Drugs

This report provides detailed exposure of the cardiovascular drugs market, highlighting major cardiovascular diseases with detailed epidemiology for the primary disease areas. The report includes an industry wide assessment of the novel product launches, recent approvals, research and development pipeline, and blockbuster drugs.

Strict regulations are imposed on cardiovascular drugs and the report discusses the regional regulatory landscape for these drugs. This includes products approved by the regulatory authorities in recent years. Products under development or that are in different stages of clinical trials are analyzed in the pipeline assessment section.

Cardiovascular drug delivery systems are also included in the report, such as nanoparticle-mediated drug delivery, gene therapy and cell therapy, among others.

A discussion of the major players is included in the competitive landscape section, which looks at trends in product launches, collaborations, mergers and acquisitions, and other agreements. Company profiles of major players operating in the cardiovascular drugs market include overviews, key product offerings, financials, strategies, SWOT analysis, and new research and development strategies.

The report will be particularly useful to readers in its thorough analysis of the leading products and will enable readers to recognize growing brands, key drug classes, and leading manufacturing companies with significant market share.

Report Includes:

  • 52 data tables and 48 additional tables
  • An overview of the global market for cardiovascular drugs
  • Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • A look at the regulatory environment, which has been a driving force in drug development
  • Information on competitor initiatives, and information with regard to demand for specialty chemicals used to develop new products and for new applications

Key Topics Covered:

1 Introduction

2 Summary And Highlights

3 Market Dynamics And Technology Background

4 Pipeline Analysis

5 Regulatory Scenario

6 Cardiovascular Drug Delivery Systems

7 Market Breakdown By Disease Areas

8 Market Breakdown By Drug Class

9 Market Breakdown By Region

10 Competitive Landscape And Key Developments

11 Company Profiles

  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astrazeneca PLC
  • Boehringer Ingelheim Gmbh
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company LTD.
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Glaxosmithkline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • United Therapeutics Corp.

For more information about this report visit

View source version on

Business Wire

Last updated on: 21/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.